“The present problem has exposed some structural weaknesses inside the EU’s medicines provide chain plus a high dependence on non-EU nations around the world for active pharmaceutical ingredients,” Kyriakides mentioned. She advisable that provide chain challenges be addressed in an EU pharmaceutical method anticipated to generally be released